Udvalget for humanmedicinske lægemidler (CHMP) konkluderede, at fordelene ved Prandin var større end risiciene ved behandling af type 2 - diabetes.
The Committee for Medicinal Products for Human Use (CHMP) decided that Prandin’ s benefits are greater than its risks for the treatment of type 2 diabetes.